US FDA Finds Serious Sanitary Violations at Two Chinese GLP-1 API Plants
According to a post by the account @ChinaSelect on October 16, 2026, inspectors from the US Food and Drug Administration (FDA) found numerous extremely serious sanitary violations at two Chinese plants producing active pharmaceutical ingredients for combination GLP-1 drugs, including black mold on equipment and extensive insect activity on ceilings, raising concerns about the safety of US pharmaceutical companies' reliance on Chinese supply chains.